Iatrogenic Cushing Syndrome Clinical Presentation
- Author: Ha Cam Thuy Nguyen, MD; Chief Editor: Romesh Khardori, MD, PhD, FACP more...
Patients with Cushing syndrome may experience weight gain, especially in the face, supraclavicular region, upper back, and torso. Frequently, patients notice changes in their skin, including purple stretch marks, easy bruising, and other signs of skin thinning. Because of progressive proximal muscle weakness, patients may have difficulty climbing stairs, getting out of a low chair, and raising their arms.
Menstrual irregularities, amenorrhea, infertility, and decreased libido may occur in women related to inhibition of pulsatile secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which likely is due to interruption of luteinizing hormone-releasing hormone (LHRH) pulse generation. In men, inhibition of LHRH and FSH/LH function may lead to decreased libido and impotence.
Psychological problems such as depression, cognitive dysfunction, and emotional lability may develop. New-onset or worsening of hypertension and diabetes mellitus, difficulty with wound healing, increased infections, osteopenia, and osteoporotic fractures may occur.
When seeing a patient with symptoms suggestive of Cushing syndrome, inquire about history of drug use, duration, and dosing, including over the counter drugs and herbal preparations. A good and detailed history can provide very useful information to exclude drug-related Cushing syndrome before proceeding with further diagnostic tests.
Patients may have increased adipose tissue in the face (moon facies), upper back at the base of neck (buffalo hump), and above the clavicles (supraclavicular fat pads).
Central obesity with increased adipose tissue in the mediastinum and peritoneum; increased waist-to-hip ratio greater than 1 in men and 0.8 in women. Increased visceral fat is easily observed and measured with CT scan of the abdomen.
Facial plethora may be present, especially over the cheeks. Violaceous striae, often wider than 0.5 cm, are observed most commonly over the abdomen, buttocks, lower back, upper thighs, upper arms, and breasts. Ecchymoses may be present. Patients may have telangiectasias and purpura.
Cutaneous atrophy with exposure of subcutaneous vasculature tissue and tenting of skin may be evident. Glucocorticoid excess may cause increased lanugo facial hair. If glucocorticoid excess is accompanied by androgen excess, as occurs in adrenocortical carcinomas, hirsutism and male pattern balding may be present in women. Steroid acne, consisting of papular or pustular lesions over the face, chest, and back, may be present. Acanthosis nigricans, which is associated with insulin resistance and hyperinsulinism, may be present. The most common sites are axilla and areas of frequent rubbing, such as over elbows, around the neck, and under the breasts.
Peptic ulceration may occur with or without symptoms. Particularly at risk are patients given high doses of glucocorticoids.
Proximal muscle weakness may be evident. Osteoporosis may lead to incident fractures and kyphosis, height loss, and axial skeletal bone pain. Avascular necrosis of the hip is also possible from glucocorticoid excess.
Patients with cushingoid features may present to the emergency department in adrenal crisis. Adrenal crisis may occur in patients on steroids who stop taking their glucocorticoids or neglect to increase their steroids during an acute illness. See Glucocorticoid Therapy and Cushing Syndrome.
Physical findings that occur in a patient in adrenal crisis include hypotension, abdominal pain, vomiting, and mental confusion (secondary to low serum sodium or hypotension). Other findings include hypoglycemia, hyperkalemia, hyponatremia, and metabolic acidosis.
The most common cause of iatrogenic, or drug-related, Cushing syndrome is glucocorticoids. Glucocorticoid use via different routes, including injected, oral, epidural, inhaled, nasal, or topical, if prolonged and potent enough, can cause Cushing syndrome.
The effect of drug interactions should be taken into consideration, especially with agents that can inhibit cytochrome P450. Via the pathway of cytochrome P450, glucocorticoid is metabolized in the liver by the CYP3A4 isoenzyme into inactive metabolites. Therefore, drugs that inhibit cytochrome P450 activity can lead to prolonged action of glucocorticoids. Cases of iatrogenic Cushing syndrome due to interaction of glucocorticoid products and cytochrome P450 inhibitors such as itraconazole, ritonavir,[11, 12] and antidepressants have been reported.
Duman and Fulco reported on a case of probable drug-induced Cushing syndrome, followed by adrenal insufficiency, caused by the concomitant use of the oral voriconazole (an antifungal, CYP3A4 inhibitor) with intranasal mometasone and inhaled fluticasone.
Epperla and McKiernan reported on a case of iatrogenic Cushing syndrome, severe osteoporosis, and adrenal insufficiency, resulting from the concomitant use of ritonavir and inhaled fluticasone in a patient with human immunodeficiency virus (HIV).
Patients with diseases that respond to steroid therapy are especially likely to receive steroids and, thus, develop Cushing syndrome. Such disorders include a wide variety of rheumatologic, pulmonary, neurological, andrenal diseases. Patients who have undergone organ transplants are also at risk for developing Cushing syndrome due to exogenous steroids required as part of graft antirejection regimens.
Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Williams textbook of endocrinology. 12th ed. Elsevier Health Sciences; May 12, 2011. 488-491.
Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP. Nuclear factor-kappaB- and glucocorticoid receptor alpha- mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation. 2005. 12(6):321-38. [Medline].
Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G, et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J. 2008 Jun. 22(6):1672-83. [Medline].
Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 1990 Sep 21. 62(6):1189-204. [Medline].
Liapi C, Chrousos GP. Glucocorticoids. Jaffe SJ, Aranda JV, eds. Therapeutic Principles in Practice. 2nd ed. Philadelphia, Pa: WB Saunders; 1992. 466-475.
Tuel SM, Meythaler JM, Cross LL. Cushing's syndrome from epidural methylprednisolone. Pain. 1990 Jan. 40(1):81-4. [Medline].
Matos AC, Srirangalingam U, Barry T, Grossman AB. Cushing's syndrome with low levels of serum cortisol: the role of inhaled steroids. Clin Med. 2011 Aug. 11(4):404-5. [Medline].
Dutta D, Shivaprasad KS, Ghosh S, Mukhopadhyay S, Chowdhury S. Iatrogenic Cushing's syndrome following short-term intranasal steroid use. J Clin Res Pediatr Endocrinol. 2012 Sep. 4(3):157-9. [Medline]. [Full Text].
Gen R, Akbay E, Sezer K. Cushing syndrome caused by topical corticosteroid: a case report. Am J Med Sci. 2007 Mar. 333(3):173-4. [Medline].
Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN. Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother. 2004 Jan. 38(1):46-9. [Medline].
Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab. 2005 Jul. 90(7):4394-8. [Medline].
Kedem E, Shahar E, Hassoun G, Pollack S. Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. J Asthma. 2010 Sep. 47(7):830-1. [Medline].
Celik O, Niyazoglu M, Soylu H, Kadioglu P. Iatrogenic Cushing's syndrome with inhaled steroid plus antidepressant drugs. Multidiscip Respir Med. 2012 Aug 29. 7(1):26. [Medline]. [Full Text].
Duman AK, Fulco PP. Adrenal Insufficiency With Voriconazole and Inhaled/Intranasal Corticosteroids: Case Report and Systematic Review. J Pharm Pract. 2016 May 4. [Medline].
Epperla N, McKiernan F. Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone. Springerplus. 2015. 4:455. [Medline]. [Full Text].
Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med. 1997 Aug 11-25. 157(15):1651-6. [Medline].
Krapf R. Development of Cushing's syndrome after use of a herbal remedy. Lancet. 2002 Dec 7. 360(9348):1884. [Medline].
Abuchaibe C, Akhtar ON. SAT-0776:Exogenous Cushing's Syndrome after Use of OTC Joint Supplement. Adrenal Case Reports 1 - CAH and Adrenal Insufficiency. Endocrine Society's 96th Annual Meeting and Expo, June 21–24, 2014 – Chicago. Available at http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2014.AHPAA.1.SAT-0776. Accessed: 4/2/15.
Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev. 1998 Oct. 19(5):647-72. [Medline].
Findling JW, Doppman JL. Biochemical and radiologic diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am. 1994 Sep. 23(3):511-37. [Medline].
Anastasopoulou C. Pseudo-Cushing Syndrome. Medscape Drugs & Diseases. Available at http://emedicine.medscape.com/article/124718-overview. Accessed: 4/3/15.
Eddy RL, Jones AL, Gilliland PF, Ibarra JD Jr, Thompson JQ, MacMurry JF Jr. Cushing's syndrome: a prospective study of diagnostic methods. Am J Med. 1973 Nov. 55(5):621-30. [Medline].
Kaye TB, Crapo L. The Cushing syndrome: an update on diagnostic tests. Ann Intern Med. 1990 Mar 15. 112(6):434-44. [Medline].
Carroll T, Raff H, Findling JW. Late-night salivary cortisol for the diagnosis of Cushing syndrome: a meta-analysis. Endocr Pract. 2009 Jul-Aug. 15(4):335-42. [Medline].
Kidambi S, Raff H, Findling JW. Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome. Eur J Endocrinol. 2007 Dec. 157(6):725-31. [Medline].
Raff H. Utility of salivary cortisol measurements in Cushing's syndrome and adrenal insufficiency. J Clin Endocrinol Metab. 2009 Jul 14. [Medline].
Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA. 1992 Mar 4. 267(9):1244-52. [Medline].
Corcept Therapeutics Incorporated announces FDA approval of Korlym (mifepristone) 300 mg tablets: First and only approved medication for Cushing’s Syndrome Patients. Corcept Therapeutics. Available at http://www.corcept.com/news_events/pr_1329524335. Accessed: February 21, 2012.
Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol. 2007 Nov. 157(5):561-9. [Medline].
Nieman L, Cutler GB Jr. Cushing's syndrome. In: Degroot LJ, Besser M, Burger HG, et al, eds. Endocrinology. 3rd ed. Philadelphia, Pa: WB Saunders; 1995. 1741-69.
Pavlatos FC, Smilo RP, Forsham PH. A rapid screening test for Cushing's syndrome. JAMA. 1965 Aug 30. 193:720-3. [Medline].
Plotz CM, Knowlton AI, Ragan C. The natural history of Cushing's syndrome. Am J Med. 1952 Nov. 13(5):597-614. [Medline].
Raff H, Findling JW. A physiologic approach to diagnosis of the Cushing syndrome. Ann Intern Med. 2003 Jun 17. 138(12):980-91. [Medline].
Yanovski JA, Cutler GB Jr. Glucocorticoid action and the clinical features of Cushing's syndrome. Endocrinol Metab Clin North Am. 1994 Sep. 23(3):487-509. [Medline].
|Type||Drug||Dose||Relative Glucocorticoid Potency||Relative Mineralocorticoid Potency||Plasma Half-Life